FTC Enters Global Settlement to Resolve Reverse-Payment Charges against Teva

The Federal Trade Commission has reached a global settlement resolving pending claims in three separate federal court antitrust lawsuits involving subsidiaries of pharmaceutical manufacturer Teva Pharmaceuticals Industries Ltd. If approved by the various courts, the stipulated order will prohibit Teva from engaging in reverse-payment patent settlement agreements that impede consumer access to lower-priced generic drugs. […]